Incidence and Outcomes of COVID-19 in People With CKD: A Systematic Review and Meta-analysis

Chung, Edmund Y. M.; Palmer, Suetonia C.; Natale, Patrizia; Krishnan, A.; Cooper, Tess E; Saglimbene, Valeria; Ruospo, Marinella; Au, Eric; Jayanti, S.; Liang, Amy; Deng, Danny; Chui, Juanita N; Higgins, Gail; Tong, Allison; Wong, Germaine; Teixeira‐Pinto, Armando; Hodson, Elisabeth M; Craig, Jonathan C.; Strippoli, Giovanni F.M.

doi:10.1053/j.ajkd.2021.07.003

Cited by 117 publications

(127 citation statements)

References 43 publications

Supporting

Mentioning

101

Contrasting

Unclassified

Order By: Relevance

“…Our results corroborated the previous results on the death rate estimated between 15 and 45% [13][14][15][16] and the prevalence of admission in intensive care units [17,18] for CKD patients.…”

Section: Discussionsupporting

confidence: 92%

“…Our study showed the value of eGFR in the death risk assessment for the CKD population for the first time. Previous studies (16,17,18) had shown how the presence of CKD or renal replacement therapy was a risk factor for death during COVID-19, but no studies addressed to assess the baseline value of eGFR in CKD patients from stage III to stage V. Only Carlson et al (12) analysis reported the vulnerability to COVID-19 in CKD according to the five stages. They showed how the risk of death is directly associated with the increasing CKD stage.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Is Previous eGFR a Reliable Risk Factor for COVID-19 Death? Single Centre Analysis in Chronic Kidney Disease Patients in Northern Italy

Martino

Fanton

Zanetti

et al. 2022

BioMed

View full text Add to dashboard Cite

COVID-19 remains a major world health problem, and its clinical manifestations can vary from an oligosymptomatic form to severe pulmonary infection, which can require invasive ventilation and is strictly related to death. Identifying risk factors for adverse outcomes is essential for performing adequate care and contrasting high mortality. Chronic kidney disease (CKD) is a widespread comorbidity and is a known risk factor for death during SARS-CoV-2 infection. The present study evaluates the death risk assessment during the COVID-19 pandemic in (CKD) patients, considering the baseline value of an estimated glomerular filtration rate (eGFR) and other possible risk factors. We retrospectively assessed the mortality risk in 150 patients with COVID-19 between 1 October and 31 December 2020. We evaluated eGFR, haemoglobin, albumin, uric acid, cholesterol, triglycerides, and significant risk factors, such as diabetes mellitus and cardiovascular disease in every patient. We had 53 deaths (35.3%) during the observational period, significantly related to age, eGFR, albumin, and baseline nephropathy. In the multivariable analysis, only baseline eGFR and age were independent predictors of death during SARS-CoV-2 infection, with an OR equal to 0.96 and 1.067, respectively. In conclusion, by our analysis, age, and the baseline eGFR were the only reliable predictors of death during COVID-19 in CKD patients.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Is Previous eGFR a Reliable Risk Factor for COVID-19 Death? Single Centre Analysis in Chronic Kidney Disease Patients in Northern Italy

Martino

Fanton

Zanetti

et al. 2022

BioMed

View full text Add to dashboard Cite

show abstract

“…Patients with end-stage kidney disease, particularly those undergoinghemodialysis, are known to have a high risk of infection and mortality from COVID-19. 7 Previous randomized controlled trials 3 demonstrated thatparticipants administered with REGEN-COV had reduced risk of COVID-19-related hospitalization and death; however, evidence on the e cacy of REGEN-COV amongpatients with end-stage kidney disease is still limited. [4][5][6] A paper reported that kidney transplant recipients administered withREGEN-COV did not require mechanical respiratory support or escalation of care to the intensive care unit.…”

Section: Discussionmentioning

confidence: 99%

Administration of Casirivimab and Imdevimab for Patient Undergoing Hemodialysis with Coronavirus Disease 2019: A Case Report and Literature Review

Shimamura

Maeda²,

Moniwa³

et al. 2022

Preprint

View full text Add to dashboard Cite

The neutralizing monoclonal antibody combination of casirivimab and imdevimab (REGEN-COV) has been reported to reduce viral load, hospitalization, and death among patients with coronavirus disease 2019 (COVID-19). However, cases of patients undergoing hemodialysis who are treated with REGEN-COV are rare. A 37-year-old Japanese patient undergoing hemodialysis presented with fever and was diagnosed with COVID-19 pneumonia. The patient had end-stage kidney disease due to diabetic nephropathy and was administered a single dose of REGEN-COV. The patient’s symptoms rapidly resolved and was discharged without complications. Our case demonstrates the effectiveness of REGEN-COV as a treatment for patients with mild COVID-19 undergoing hemodialysis.

show abstract

“…Organ specific manifestations, which include the liver and the kidney along with their possible mechanism of injury have been available in literature [ 18 ]. A systematic review and meta-analysis of the published studies indicate that COVID-19 incidence was higher in people receiving maintenance dialysis than in those with CKD not requiring kidney replacement therapy or those who were kidney or pancreas/kidney transplant recipients [ 19 ]. In patients with COVID-19, acute Kidney Injury (AKI) may have an inflammatory etiology mediated by a cytokine storm [ 20 ].…”

Section: Discussionmentioning

confidence: 99%

Determinants of severity among hospitalised COVID-19 patients: Hospital-based case-control study, India, 2020

et al. 2021

View full text Add to dashboard Cite

Background Risk factors for the development of severe COVID-19 disease and death have been widely reported across several studies. Knowledge about the determinants of severe disease and mortality in the Indian context can guide early clinical management. Methods We conducted a hospital-based case control study across nine sites in India to identify the determinants of severe and critical COVID-19 disease. Findings We identified age above 60 years, duration before admission >5 days, chronic kidney disease, leucocytosis, prothrombin time > 14 sec, serum ferritin >250 ng/mL, d-dimer >0.5 ng/mL, pro-calcitonin >0.15 μg/L, fibrin degradation products >5 μg/mL, C-reactive protein >5 mg/L, lactate dehydrogenase >150 U/L, interleukin-6 >25 pg/mL, NLR ≥3, and deranged liver function, renal function and serum electrolytes as significant factors associated with severe COVID-19 disease. Interpretation We have identified a set of parameters that can help in characterising severe COVID-19 cases in India. These parameters are part of routinely available investigations within Indian hospital settings, both public and private. Study findings have the potential to inform clinical management protocols and identify patients at high risk of severe outcomes at an early stage.

show abstract

Incidence and Outcomes of COVID-19 in People With CKD: A Systematic Review and Meta-analysis

Cited by 117 publications

References 43 publications

Is Previous eGFR a Reliable Risk Factor for COVID-19 Death? Single Centre Analysis in Chronic Kidney Disease Patients in Northern Italy

Is Previous eGFR a Reliable Risk Factor for COVID-19 Death? Single Centre Analysis in Chronic Kidney Disease Patients in Northern Italy

Administration of Casirivimab and Imdevimab for Patient Undergoing Hemodialysis with Coronavirus Disease 2019: A Case Report and Literature Review

Determinants of severity among hospitalised COVID-19 patients: Hospital-based case-control study, India, 2020

Contact Info

Product

Resources

About